IS, Sinclair to be one in share swap merger?
This article was originally published in Scrip
Two UK-based specialty companies, Sinclair Pharma and IS Pharma, are in "advanced discussions regarding a possible merger" to create Sinclair IS Pharma. The combined company could boost market access for specialty products across Europe, the companies claim.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.